CONTACT US: Contact info
|
Citation |
Fragkaki AG, Georgakopoulos C, Sterk S, Nielen MW. Clin. Chim. Acta 2013; 425: 242-258. |
|
Affiliation |
Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", Kifisias 37, 15123, Maroussi, Greece. Electronic address: argyteo@ath.forthnet.gr. |
|
Copyright |
(Copyright © 2013, Elsevier Publishing) |
|
DOI |
|
PMID |
23954776 |
|
Abstract |
beta2-Adrenergic agonists, or β2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel β2-agonists molecules either by modifying the molecule of known β2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future. Language: en |